Company intelligence / Profile preview

Alnair Therapeutics

Chicago, Illinois, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Pre-clinical studies in animal models have demonstrated significant increases in tumor targeting and drug penetration using Alnair’s platform. In triple negative breast cancer models, survival rates were improved by a factor of 3.5 compared to conventional therapy. The company has recently closed an oversubscribed $1M+ pre-seed funding round and won several innovation awards.

Therapeutic areas: Oncology
Modalities: Drug delivery platform compatible with oncolytic, targeted, immune, and hormone therapies
Industry: Biotech

Drug pipeline

3 assets

ALN-Cytotoxic Chemotherapy

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Alnair Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alnair Therapeutics.

Explore the full profile